Source:http://linkedlifedata.com/resource/pubmed/id/17564319
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2007-6-13
|
pubmed:abstractText |
Tamoxifen was used to determine the effects of N-acetyltransferase(NAT) activity and 2-aminofluorene (2-AF)-DNA adduct formation in human breast cancer cells. Breast cancer cells were categorized into two groups based on the status of estrogen receptor, ER (+) and ER (-). 2-AF-DNA adduct formations in breast cancer cells are 2.58 +/- 0.39 pmol adduct/mg DNA for ER (+) and 2.74 +/- 0.46 pmol adduct/mg DNA for ER (-), respectively. Co-treatment with 1 microM tamoxifen inhibited DNA-adduct formations up to 65% in ER (+) and 61% in ER (-), respectively. The inhibition of Tamoxifen on DNA adduct formation between ER (+) and ER (-) cell was not significantly different. The results of the N-acetyltransferase activity in human breast cancer cells were inhibited by tamoxifen in a dose dependent manner. Tamoxifen inhibited 50.0% and 42.8% of Km in ER (+) and ER (-), 58.2% and 35.6% of Vmax, respectively. Based on the kinetic study of N-acetyltransferase activity, tamoxifen plays a non-competitive role in the acetylation reaction. This study demonstrates that tamoxifen inhibited not only NAT activity but also DNA-adduct formation in human breast cancer cells, regardless of the status of estrogen receptor. These findings could provide a clue that tamoxifen has chemoprevention effects in breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-aminofluorene,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Arylamine N-Acetyltransferase,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinogens,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Adducts,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorenes,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1078-0297
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
115-116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
217-33
|
pubmed:meshHeading |
pubmed-meshheading:17564319-Acetylation,
pubmed-meshheading:17564319-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17564319-Arylamine N-Acetyltransferase,
pubmed-meshheading:17564319-Breast Neoplasms,
pubmed-meshheading:17564319-Carcinogens,
pubmed-meshheading:17564319-Cell Line, Tumor,
pubmed-meshheading:17564319-DNA Adducts,
pubmed-meshheading:17564319-Dose-Response Relationship, Drug,
pubmed-meshheading:17564319-Fluorenes,
pubmed-meshheading:17564319-Humans,
pubmed-meshheading:17564319-Kinetics,
pubmed-meshheading:17564319-Receptors, Estrogen,
pubmed-meshheading:17564319-Tamoxifen
|
pubmed:year |
2004
|
pubmed:articleTitle |
Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells.
|
pubmed:affiliation |
Department of Surgery, China Medical University Hospital, Taichung 404, Taiwan, ROC. jauhong@yahoo.com
|
pubmed:publicationType |
Journal Article
|